Le Lézard
Classified in: Health
Subjects: CCA, ACC

Invitation to presentation of RaySearch's interim report for the second quarter of 2023


STOCKHOLM, Aug. 8, 2023 /PRNewswire/ -- Analysts, investors, and the media are invited to a presentation of RaySearch's interim report for the second quarter of 2023 on August 25, 2023, at 10.00 am CEST. The report will be published on August 25, 2023, at 07.45 am and will be available together with presentation slides on raysearchlabs.com. Johan Löf, founder and CEO, and Annika Blondeau Henriksson, interim CFO, will present the company's development in a webcast. After the presentation (held in English) there is the opportunity to ask questions.

Link to webcast: https://raysearchlabs.creo.se/230825/

Or dial in to join the webcast:
Sweden: +46 (0) 8 5051 0031
United Kingdom: +44 (0) 207 107 06 13
United States: +1 (1) 631 570 56 13

For more information, please contact:
Johan Löf, founder and CEO, RaySearch Laboratories AB (publ)
Telephone: +46 (0) 8 510 530 00
[email protected]

Annika Blondeau Henriksson, interim CFO, RaySearch Laboratories AB (publ) 
Telephone: +46 (0) 8 510 530 00
[email protected]

The following files are available for download:

https://mb.cision.com/Main/1102/3814732/2218376.pdf

RaySearch Press Release August 8, 2023

 

SOURCE RaySearch Laboratories


These press releases may also interest you

at 10:05
Puma Biotechnology, Inc. , a biopharmaceutical company, announced the presentation of biomarker findings from a Phase II randomized clinical trial of alisertib alone vs. alisertib + fulvestrant for the treatment of patients with endocrine and CDK4/6...

at 10:00
Leading international medical research company, MEDSIR, today announced the results of the recent PRIMED clinical trial during the 2024 ASCO Annual...

at 10:00
Flamingo Therapeutics ("Flamingo") today announced the presentation of a Trial-in-Progress poster at the 2024 Annual Meeting of the American Society of Clinical Oncology (ASCO 2024) taking place in Chicago,...

at 09:35
Tempus, a leader in artificial intelligence and precision medicine, announced new testing solutions to help physicians identify patients with HER2 or FOLR1 expressing tumors, which may make such patients eligible for targeted therapies such as...

at 09:30
Tolmar Inc., a fully integrated pharmaceutical company, today announced results from a landmark survey of more than 300 US physicians, revealing...

at 08:42
Bio-Thera Solutions Inc. (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, will present a poster at the 2024 ASCO Annual Meeting entitled "Phase 1 study of BAT8006, a folate...



News published on and distributed by: